spacer
home > pmps > autumn 2003 > cryogenics leads the way in emissions control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Cryogenics Leads the Way in Emissions Control

Emissions control has long been an important management issue for pharmaceutical manufacturers in Europe and beyond, but emerging legislation implemented throughout EU member states is forcing the industry to take a closer look at abatement technologies in search of solutions which will ensure compliance not just now, but in the future too.

Legislation puts Focus on Solvent Recovery

The manufacture of pharmaceutical products is reliant on a number of organic solvents, producing emissions in a number of process areas - from reactor vents to storage tanks and vacuum pumps. Dichloromethane, methanol, ethyl acetate, acetone, toluene, xylene, triethylamine, tetrahydrofurane, butyl acetate and isopropanol are among the VOCs regularly used by pharmaceutical manufacturers and legislation is limiting these emissions year on year. Industrial emissions to the atmosphere first became a focus of environmental regulation with the introduction of the Clean Air Act in 1993. Since then increasing concern about the effect of air pollutants on the environment has led to the development of the UK's National Air Quality Strategy, setting targets which are to be achieved by 2005.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Diana Raine, Business Manager for Cryogenics in Europe at Air Products

Diana Raine is Air Products' Business Manager for cryogenics in Europe and specialises in finding applications for cryogenic technology in modern industrial processes. She joined the company 12 years ago with a Masters in Chemical Engineering.

spacer
Diana Raine
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) a subsidiary of WuXi AppTec and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement